Eli Lilly and Novo can 'coexist for awhile' in the weight-loss drug space, says BMO's Evan SeigermanПодробнее
Eli Lilly weight loss drugs are 'mega-growth assets' BMO's Evan Seigerman saysПодробнее
Eli Lilly's obesity drug will be a tailwind for the stock, says BMO's Evan SeigermanПодробнее
